omniture
科兴生物制药股份有限公司

Latest News

Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at CPHI Frankfurt 2025

FRANKFURT, Germany, Oct. 31, 2025 /PRNewswire/ -- From October 28th to 30th, Kexing Biopharm partic...

2025-10-31 19:50 1562

Kexing Biopharm's Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF

SHENZHEN, China, Sept. 16, 2025 /PRNewswire/ -- Kexing Biopharm announced that its investigational ...

2025-09-17 10:30 1273

Kexing Biopharm's GB18 project received clearance of IND application from NMPA and FDA

SHENZHEN, China, May 28, 2025 /PRNewswire/ -- On May 26th, Kexing Biopharm (688136.SH) announced th...

2025-05-29 11:47 1385

May 19: World Inflammatory Bowel Disease Day | Healthy Gut, Happy Life

SHENZHEN, China, May 26, 2025 /PRNewswire/ -- May 19 is designated as World Inflammatory Bowel Dise...

2025-05-26 21:24 2018

Kexing Biopharm Obtained IND Approval for Its Self-developed GB05 from U.S. FDA

SHENZHEN, China, Feb. 14, 2025 /PRNewswire/ -- Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) re...

2025-02-14 21:00 2982

Kexing Biopharm Participates in the 17th Biotech Showcase, with Multiple Innovation Pipelines Gaining Attention

SHENZHEN, China, Jan. 24, 2025 /PRNewswire/ -- From January 13 to 16, Dr. Huiming Li, Deputy Genera...

2025-01-24 14:59 3162

Kexing Biopharm's Albumin-bound Paclitaxel Granted EU Market Approval

SHENZHEN, China, July 31, 2024 /PRNewswire/ -- On July 28 2024, Kexing Biopharm announced European ...

2024-07-31 18:33 3169

Kexing Biopharm Obtained Clinical Trial Approval for its Self-developed Class I Innovative Drug--Long-acting Growth Hormone

SHENZHEN, China, May 30, 2024 /PRNewswire/ -- On the 24th of May, Kexing Biopharm (688136.SH) annou...

2024-05-30 17:09 2029

Kexing Biopharm Facility Passes EU GMP Certification for Paclitaxel for Injection (Albumin Bound)

SHENZHEN, China, May 10, 2024 /PRNewswire/ -- On the evening of May 5, Kexing Biopharm (stock code:...

2024-05-10 20:07 3002

R&D Progress: Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm

SHENZHEN, China, April 10, 2024 /PRNewswire/ -- Recently, Kexing Biopharm (688136.SH) announced tha...

2024-04-10 11:41 3191

Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio

SHENZHEN, China, Jan. 5, 2024 /PRNewswire/ -- On the morning of January 3, Kexing Biopharm signed a...

2024-01-05 19:44 3751

Kexing Biopharm Attended CPHI Worldwide 2023

SHENZHEN, China, Nov. 7, 2023 /PRNewswire/ -- Recently, CPHI Worldwide 2023 was successfully held i...

2023-11-07 20:09 1957

Kexing Biopharm Holds China-MENA & South Asia Pharmaceutical Cooperation High-end Forum, Aiming at Foreign Emerging Markets

SHENZHEN, China, Oct. 9, 2023 /PRNewswire/ -- The 2023 China-MENA & South Asia Pharmaceutical Coope...

2023-10-09 19:09 2166

"Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery"

SHENZHEN, China, Sept. 25, 2023 /PRNewswire/ -- On September 15, "Kexing Biopharm 2023 Innovation F...

2023-09-25 15:31 2625

Kexing Biopharm Makes it into China's Top 20 Biopharmaceutical Enterprises (Blood Products, Vaccines and Insulin) for Two Consecutive Years

SHENZHEN, China, July 7, 2023 /PRNewswire/ -- Kexing Biopharmaceutical (688136.SH) has accomplished...

2023-07-07 19:43 5445

Congratulations! Kexing Biopharm (688136.SH) was awarded by the" Annual Top 20 Chinese Biopharmaceutical Entreprises"

SHENZHEN, China, July 21, 2022 /PRNewswire/ -- On 12 July 2022, Menet held the award ceremony of th...

2022-07-21 22:32 3862